Neurocrine Biosciences, Inc. (NBIX) 株式分析

企業概要

Neurocrine Biosciences, Inc. is engaged in the discovery, development, and commercialization of pharmaceutical products designed to treat neurological, psychiatric, endocrine, and immunological disorders across both domestic and international markets. This operational focus places the firm within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, which distinguishes its products as specialized therapeutics rather than generic commodities. The company operates with a substantial scale, evidenced by a market capitalization of $13.21B and an annual revenue of $2.86B, supported by a workforce of approximately 2000 employees. These financial dimensions indicate that Neurocrine Biosciences, Inc. holds a significant position within its niche, commanding a valuation that reflects its established product portfolio and ongoing research capabilities in specialized medical fields.

財務健全性

The company reported a total revenue of $2.86B over the trailing twelve months, generating a net income of $478.60M and an EBITDA of $666.60M. The substantial gap between the revenue figure and the net income reveals a cost structure where operating expenses, including research and development costs, amount to approximately $2.38B, highlighting the capital-intensive nature of pharmaceutical manufacturing and sales. The free cash flow stands at $397.81M, which signifies strong financial flexibility allowing the company to fund operations, invest in R&D, or manage capital expenditures without relying on external financing. Profitability is further illustrated by a gross margin of 62.7%, an operating margin of 28.2%, and a profit margin of 16.7%, indicating that the company retains a significant portion of revenue after accounting for production costs, operating expenses, and taxes. On the liability side, the company holds $1.48B in cash against $471.30M in debt, resulting in a debt-to-equity ratio of 14.49, which suggests a conservative balance sheet with ample liquidity to cover obligations. The current ratio of 3.39 indicates a robust short-term liquidity position, meaning the company possesses more than three times the current assets necessary to settle its current liabilities. Furthermore, the return on equity of 16.4% and return on assets of 9.5% demonstrate that management is effectively utilizing shareholder capital and company assets to generate profitable returns.

バリュエーション評価

Valuation metrics indicate a trailing P/E ratio of 28.19 and a forward P/E of 15.39, suggesting that the market expects a significant acceleration in earnings growth to justify the higher trailing multiple relative to the more accessible forward multiple. The price-to-book ratio is recorded at 4.05, indicating that the stock trades at a substantial premium over its book value, which often reflects investor confidence in the intangible assets and future growth potential of the pharmaceutical pipeline. Alternative valuation measures such as the price-to-sales ratio of 4.62 and an EV/EBITDA of 18.31 provide context that the company is priced for growth relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. Regarding price action, the 52-week high is $160.18 and the 52-week low is $84.23, placing the current market price within a range that has experienced notable volatility over the last year. The beta value of 0.35 indicates that the stock exhibits low price volatility, moving with significantly less intensity than the broader market index, which makes it a relatively stable holding compared to high-beta technology or biotech peers.

Growth & Income

Revenue growth for the trailing twelve months is 28.3%, while earnings growth is 47.7%, implying that earnings are expanding at a rate significantly faster than revenue, which is a common characteristic of successful pharmaceutical companies as pricing power or cost efficiencies materialize. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, indicating a strategic decision to reinvest all net income into research, development, and commercial expansion rather than distributing cash to shareholders. This reinvestment strategy supports the company's growth profile, allowing for the advancement of its product pipeline in neurological and psychiatric disorders without the constraint of regular dividend obligations. Overall, Neurocrine Biosciences, Inc. presents a growth-oriented profile characterized by strong earnings expansion, a conservative capital structure, and a valuation that anticipates future performance improvements.